| The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis CR Chapple, V Khullar, Z Gabriel, D Muston, CE Bitoun, D Weinstein European urology 54 (3), 543-562, 2008 | 929 | 2008 |
| Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial V Khullar, G Amarenco, JC Angulo, J Cambronero, K Høye, I Milsom, ... European urology 63 (2), 283-295, 2013 | 550 | 2013 |
| The impact of overactive bladder on mental health, work productivity and health‐related quality of life in the UK and Sweden: results from EpiLUTS KS Coyne, CC Sexton, ZS Kopp, C Ebel‐Bitoun, I Milsom, C Chapple BJU international 108 (9), 1459-1471, 2011 | 283 | 2011 |
| Flexible‐dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double‐blind, placebo‐controlled study of fesoterodine in an aging population trial A Wagg, V Khullar, D Marschall‐Kehrel, MC Michel, M Oelke, A Darekar, ... Journal of the American Geriatrics Society 61 (2), 185-193, 2013 | 118 | 2013 |
| The relationship between BMI and urinary incontinence subgroups: results from EpiLUTS V Khullar, CC Sexton, CL Thompson, I Milsom, CE Bitoun, KS Coyne Neurourology and urodynamics 33 (4), 392-399, 2014 | 114 | 2014 |
| The impact of OAB on sexual health in men and women: results from EpiLUTS KS Coyne, CC Sexton, C Thompson, ZS Kopp, I Milsom, SA Kaplan The Journal of Sexual Medicine 8 (6), 1603-1615, 2011 | 109 | 2011 |
| Long‐term safety, tolerability and efficacy of flexible‐dose fesoterodine in elderly patients with overactive bladder: open‐label extension of the SOFIA trial A Wagg, V Khullar, MC Michel, M Oelke, A Darekar, CE Bitoun Neurourology and urodynamics 33 (1), 106-114, 2014 | 63 | 2014 |
| Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland G McCarthy, CE Bitoun, H Guy Value in Health 16 (7), A558, 2013 | 39 | 2013 |
| Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation L Cardozo, T Hall, J Ryan, C Ebel Bitoun, I Kausar, A Darekar, A Wagg International urogynecology journal 23, 1581-1590, 2012 | 27 | 2012 |
| Clinical value of a patient‐reported goal‐attainment measure: the global development of self‐assessment goal achievement (SAGA) questionnaire for patients with lower urinary … V Khullar, M Espuna‐Pons, D Marschall‐Kehrel, A Fianu‐Jonasson, ... Neurourology and urodynamics 33 (1), 90-94, 2014 | 16 | 2014 |
| Effects of drug cessation after flexible‐dose fesoterodine in patients with overactive bladder V Khullar, L Cardozo, CJ Kelleher, T Hall, J Ryan, C Ebel Bitoun, ... BJU international 112 (6), 820-829, 2013 | 12 | 2013 |
| 880 ASSESSMENT OF FESOTERODINE TREATMENT IN OLDER PEOPLE WITH OVERACTIVE BLADDER: RESULTS OF SOFIA, A DOUBLE-BLIND, PLACEBO-CONTROLLED PAN EUROPEAN TRIAL A Wagg, V Khullar, D Marschall-Kehrel, MC Michel, M Oelke, DG Tincello, ... European Urology Supplements 2 (10), 276-277, 2011 | 9 | 2011 |
| An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material T Schneider, D Arumi, TJ Crook, F Sun, MC Michel International Journal of Clinical Practice 68 (9), 1074-1080, 2014 | 8 | 2014 |
| Understanding Swedish patients’ expectations for treatment of their urinary symptoms A Fianu-Jonasson, L Brubaker, C Kelleher, V Khullar, CE Bitoun, ... Nordic Urogynecological Association, 2009 | 7 | 2009 |
| The prevalence of OAB in the US, UK, and Sweden: results from EPILUTS KS Coyne, CC Sexton, D Weinstein, ZS Kopp, C Ebel-Bitoun, I Milsom, ... The Journal of Urology 181 (4S), 160-160, 2009 | 3 | 2009 |
| The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis Editorial Comment CR Chapple, V Khullar, Z Gabriel, D Muston, CE Bitoun, D Weinstein JOURNAL OF UROLOGY 181 (6), 2649-2650, 2009 | 2 | 2009 |
| 687 Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence T Schneider, A Bergqvist, J Wang, A Wagg, C Ebel-Bitoun European Urology Supplements 1 (11), e687, e687a, 2012 | 1 | 2012 |
| Efficacy and Tolerability of Fesoterodine in Older Subjects With Overactive Bladder: Results of SOFIA AS Wagg, V Khullar, D Marschall-Kehrel, MC Michel, M Oelke, A Darekar, ... Journal of the American Geriatrics Society 59, S124-S124, 2011 | 1 | 2011 |
| O616 The impact of OAB on female sexual health: The EpiLUTS study I Milsom, K Coyne, C Sexton, CE Bitoun, D Weinstein, Z Kopp International Journal of Gynecology & Obstetrics 107, S268-S269, 2009 | 1 | 2009 |
| 58 THE PREVALENCE OF OAB IN SWEDEN, UK, AND US AND ITS ASSOCIATION WITH ANXIETY AND DEPRESSION, AND WORK PRODUCTIVITY: RESULTS FROM EPILUTS KS Coyne, C Sexton, D Weinstein, I Milsom, CE Bitoun, Z Kopp, ... European Urology Supplements 4 (8), 135, 2009 | 1 | 2009 |
